Vaccine type |
Age,
Number of doses |
Route and dose |
Minimum dosing interval (months) |
Notes |
Diphtheria Tetanus
Pertussis (DTP, dTp) |
<4 years
4 or 5 doses DTPa |
IM
0.5 ml |
1,1*,6** |
3 doses for primary series then **4th dose at 18 months of age or 6 months after primary course. If 4 doses of DTP given before age 18 months, give a 5th dose at 4 years, reflecting the NIP which includes dose 4 at 18 months and dose 5 at 4 years. If the 4th dose is given after the child is 3.5 years the 5th dose is not required, and in this case the next dose is the early adolescent booster dose. A hexavalent vaccine is available in all jurisdictions, (combining DTPa with IPV/Hib/HepB). *If using the hexavalent vaccine combined with hepatitis B, the dosing interval changes (2 months between doses 2 and 3 and 4 months between dose 1 and 3). |
4-9 years
4 doses DTPa |
IM
0.5 ml |
1,1*,6** |
3 doses for primary series then **4th dose 6 months after primary course. Hexavalent vaccine as above. |
10 years and older
3 doses (dTpa) |
IM
0.5 ml |
1,1 |
Up to 3 doses of dTpa may now be used (previously dTpa, dT, dT), then 10-year and 20-year booster dTpa. dTpa is now available combined with IPV (dTpa-IPV).
dTpa is also recommended for pregnant women between 20-32 weeks gestation in every pregnancy (can be given any time up to delivery); partners of women who are at least 28 weeks gestation if no booster for 10 years, and parents of children <6 months if no booster for 10 years. |
Measles
Mumps
Rubella (MMR)
(LAV) |
<10 years
2 doses |
IM or SC*
0.5 ml |
1 |
2nd dose due at 3.5–4 years if
<3.5 years at first dose.
MMR (*given IM) is now available combined with Varicella Vaccine (VV) as MMR-V (*given SC) – although MMR-V is not recommended as the first dose of MMR containing vaccine in children
<4 years, due to increased risk of fever/febrile convulsions in this setting.
Recent changes (April 2019) have lowered the recommended age at which infants can receive MMR in special circumstances - from 9 months to 6 months. Infants 6 months and older can receive MMR as post-exposure prophylaxis, or during outbreaks (or for travel to endemic areas). |
10 years and older (born 1966 or later)
2 doses |
IM or SC*
0.5 ml |
1 |
Note: MMR now given as part of Departure Health Check for Offshore Humanitarian arrivals aged 9 months – 54 years, consider timing if administering TST for tuberculosis (TB) screening or live viral vaccines.
MMR-V (*given SC) can be given as the first dose in children 4 years and older (followed by MMR alone), but is not recommended in those aged 14 years and older. |
Inactivated
Poliomyelitis Vaccine (IPV) |
<4 years
4 doses*
4 years and older
3 doses |
Varies** 0.5 ml |
1,1, varies*
1,1 |
*4th dose required if aged
<4 years for primary course. Different combination vaccines available, combined with DTPa/dTpa/HiB/Hep B. Hexavalent vaccine dosing as above. Also available as dTpa-IPV.
**IPV in combination vaccines given IM, IPV alone given SC. Note: OPV and IPV are considered interchangeable (OPV may have been given prior to travel to Australia from
certain countries). |
Hepatitis B |
<11 years
3 doses |
IM
0.5 ml |
1,2** |
Combination vaccines are available, *dosing intervals complex, minimal dosing intervals: 1 month between dose 1 and 2; 2 months between doses 2 and 3; and 4 months between dose 1 and 3. |
11-15 years
2 doses (adult formulation) |
IM
1 ml |
4 |
Alternate regimen is 3 doses paediatric formulation (0.5 ml) as above. |
16 years and older
3 doses* |
IM
varies** |
1,2** |
*Age 16–19 years 3 doses paediatric formulation (0.5 ml), 20 years and older 3 doses adult formulation (1 ml). Dosing intervals as above. |
Meningococcal ACWY |
Any*
1 or 2 doses** |
IM
0.5 ml |
(2) |
*Normally given at age 12 months, disease has bimodal peaks in incidence of
<5 years and 15–24 years, MenC catch-up previously funded to 19 years (born>1987). Consider providing MenACWY if previous meningococcal vaccination was provided as MenC.
**Nimenrix = 1 dose, Menveo/Menactra = 2 doses, 8 weeks apart. |
15-19 years (year 10 or equivalent) 1 dose |
IM 0.5 ml |
– |
Also provided for year 10 students (and available in Victoria for those aged 15–19 years, State-based program).
Additional
doses of meningococcal ACWY vaccine recommended in asplenia. |
Haemophilus
influenzae
type b (Hib) |
2-17 months
1-3 doses then booster*
18-59 months
1 dose |
IM
0.5 ml |
1 or 2*
varies* 2 |
Required in children
<5 years of age. Not required 5 years and older, unless special circumstances, including
asplenia but may be given as part of combination vaccines. Children
<10 years generally receive multiple doses of Hib through the use of combination vaccines (e.g. hexavalent DTPa/IPV/HiB/HepB).
Refer to Immunisation Handbook for catch-up schedule in younger children – <7 months – 3 doses then booster at 18 months, 7–11 months 2 doses then booster at 18 months, 12–17 months 1 dose then booster at 18 months or 2 months after last dose (whichever is later). If a child has received PRP-OMP Hib vaccine for the first 2 doses, they do not require a 3rd dose but should still have a booster at 18 months. |
Pneumococcal
conjugate (13vPCV) |
<12 months
3 doses
12–59 months
1 dose |
IM 0.5 ml |
1,1
–
|
Now given at 2,4 and 12 months of age in NIP, with an extra dose at 6m for children with medical risk factors.
Required in all children
<5 years of age, and 5 years and older if medical risk factors. If providing catch-up for children who have medical risk factors:
<12 months – 4 doses required, and 12-59 months – 2 doses required. Dosing interval is 1 month for <12 months age or 2 months for 12 months of age and older.
People with medical risk factors require extra doses of 13vPCV and 23vPPV
(minimum 8 weeks apart) see Immunisation Handbook. |
Pneumococcal polysaccharide (23vPSV) |
65 years |
IM 0.5 ml |
– |
Age 65 years and older.
People with medical risk factors as above. See Immunisation Handbook. |
Varicella (VV)
(LAV) |
18 months –
13 years
1 dose
14 years and older*
2 doses |
SC
0.5 ml |
–
1 |
All children
<14 years should have at least one dose of VV (and preferably two doses of VV), usually given as either VV or MMR-V at 18 months. Prior varicella infection is not a contraindication. If varicella containing vaccine is given
<12 months of age, the dose should be repeated at 18 months. MMR-V is not recommended as the first dose of MMR containing vaccine in children <4 years, due to increased risk of fever/febrile convulsions, and is not recommended in those aged 14 years and older.
*VV is recommended in non-immune adolescents/adults 14 years and older (no clinical history and negative serology). People 14 years and older with a reliable history of varicella should be considered immune; check serology if no clinical history of varicella infection. |
Herpes zoster (LAV) |
70-79 years
1 dose |
SC
0.5 ml |
– |
Recommended at age 70 years, 5-year catch-up program available for those age 71–79 years (starting 2018). Exclude previous dosing and contraindications, and check
decision aid. |
Human Papilloma Virus (HPV) |
12-14 years
2 doses
15 years and older*
3 doses |
IM
0.5 ml |
6
2,6 |
From 2018, 9-valent HPV given to all year 7 students (or age equivalent 12-13 years). 2-dose course
<15 years (0,6-12 months) and *3-dose course 15 years and older or immunocompromised (0, 2, 6 months). Also see Immunisation Handbook .
9-valent HPV funded up to and including age 19 years. HPV vaccines not recommended during pregnancy, can be given during breastfeeding. 4-valent HPV recommended and funded in Victoria funded for MSM population until 31 October 2019. Licensed for females age 9–45 years and males 9–26 years. |
Influenza (seasonal and annual) |
<9 years
1 or 2 doses*
9 years and older 1 dose
|
IM (dose varies) |
1
– |
Now recommended annually for all people 6 months and older, including pregnant women. In Victoria, funded for children
<5 years (from 2018), pregnant women, adults 65 years and older, and age 5 years and older with medical risk factors.
Dose and formulation vary with age and formulation – 0.5 ml age 6 months and older (Fluarix Tetra, Vaxigrip Tetra, FluQuadri), 0.5 ml 3 years and older (previous and also Influvac Tetra), 0.5 ml 5 years and older (previous and also Afluria Quad). Different formulations funded for adults 65 years and older (Fluad Quad 0.5 ml). *If aged
<9 years at the time of first administration – 2 doses minimum 1 month apart. Check Immunisation Handbook and
MVEC information . |
Rotavirus
(LAV) |
<6 months,
2 doses* |
Oral 1.5 ml |
1 |
Not usually given
as catch-up due to strict age restrictions. Rotarix (1.5 ml): 2 doses at 2 and 4 months of age, 1st dose must be given
<15 weeks, 2nd dose must be given <25 weeks. |
Bacillus Calmette
Guerin (BCG)
(LAV) |
<16 years*,
1 dose |
ID,
varies** |
– |
Recommended in:1,2
Children
<5 years in households with immigrants/unscreened visitors from high prevalence countries.
Children
<5 years travelling to high prevalence countries (i.e.>40 cases per 100,000 population per year) for >3 months (also consider cumulative travel).
Neonates with family history of leprosy.
*Consider in:
Exposure to active pulmonary TB where preventive therapy not possible/after completion preventive therapy.
Travel to high prevalence area >6 weeks if aged
<5 years, >3 months aged >5 years.[2]
Only give if no record/scar, no immunosuppression, no evidence TB infection (requires TST if previous travel, usually no TST if age
<2 years and no travel) and no other contraindications. **Dose is 0.05ml age <12 months, 0.1ml 12 months and older. Only available through RCH and Monash currently. |